Drug profile

The FDA adverse-event record for Phosphate Binder (Unspecified)

33 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Phosphate Binder (Unspecified). See the species affected, top reactions, and outcomes below.

33
adverse-event reports
15.2%
death-coded share
Cat
most-reported species
13
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
33
Total Reports
5
Deaths Reported
15.2%
Death Rate

Active Ingredients

Phosphate Binder (Unspecified)

Administration Routes

UnknownOralSubcutaneous

Species Affected

Cat 29
Dog 4

Most Affected Breeds

Domestic Shorthair 17
Cat (unknown) 6
Domestic Longhair 2
Domestic Mediumhair 2
Chihuahua 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Shih Tzu 1
Himalayan 1
Persian 1
Dog (unknown) 1

Most Reported Reactions

Lack of efficacy - NOS 13
Weight loss 7
Decreased haematocrit 6
Decreased appetite 4
Elevated creatinine 4
Lethargy (see also Central nervous system depression in Neurological) 3
Elevated symmetrical dimethylarginine (SDMA) 3
Hyperphosphataemia 3
Diarrhoea 3
Death by euthanasia 3
Dehydration 3
Pica NOS 2

Outcome Breakdown

Outcome Unknown
14 (42.4%)
Ongoing
12 (36.4%)
Euthanized
3 (9.1%)
Recovered/Normal
2 (6.1%)
Died
2 (6.1%)

Phosphate Binder (Unspecified) Adverse Event Insights

33 reports name Phosphate Binder (Unspecified); 5 recorded a death outcome (15.2% of reported events, not a population-level mortality rate). Active ingredient: Phosphate Binder (Unspecified). Administration routes: Unknown, Oral, Subcutaneous.

By species: Cat (29 reports), Dog (4 reports). By breed: Domestic Shorthair (17), Cat (unknown) (6), Domestic Longhair (2).

Leading clinical signs: Lack of efficacy - NOS (13), Weight loss (7), Decreased haematocrit (6), Decreased appetite (4). Outcome, 33 coded reports: Outcome Unknown leads at 42.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.